See more : Pou Chen Corporation (9904.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Helius Medical Technologies, Inc. (HSDT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helius Medical Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- WELLYSUN INC (6988.TW) Income Statement Analysis – Financial Results
- Ascom Holding AG (0QON.L) Income Statement Analysis – Financial Results
- Canxgold Mining Corp. (GDMRF) Income Statement Analysis – Financial Results
- Vertu Motors plc (VTMTF) Income Statement Analysis – Financial Results
- ACP Energy Plc (ACPE.L) Income Statement Analysis – Financial Results
Helius Medical Technologies, Inc. (HSDT)
About Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 644.00K | 787.00K | 522.00K | 661.00K | 1.50M | 478.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 583.00K | 463.00K | 298.00K | 388.00K | 846.00K | 0.00 | 0.00 | 0.00 | 171.78K | 0.00 | 0.00 |
| Gross Profit | 61.00K | 324.00K | 224.00K | 273.00K | 650.00K | 478.00K | 0.00 | 0.00 | -171.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 9.47% | 41.17% | 42.91% | 41.30% | 43.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.94M | 4.26M | 5.99M | 4.58M | 8.06M | 9.94M | 14.39M | 4.72M | 3.83M | 171.78K | 4.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.21M | 8.47M | 5.65M | 4.26M | 895.50K | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 774.40K | 0.00 | 0.00 |
| SG&A | 9.27M | 10.64M | 12.18M | 9.71M | 16.52M | 17.21M | 8.47M | 5.65M | 5.04M | 895.50K | 4.27M |
| Other Expenses | 276.00K | 181.00K | 200.00K | 363.00K | 64.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.49M | 15.08M | 18.37M | 14.66M | 24.65M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Cost & Expenses | 13.07M | 15.55M | 18.66M | 15.05M | 25.49M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Interest Income | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.00K | 20.07K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 1.95M | 5.17M | 1.67M | 176.49K | 0.00 | 0.00 |
| Depreciation & Amortization | 162.00K | 306.00K | 374.00K | 482.00K | 191.00K | 59.00K | 17.00K | 1.78M | 20.07K | 0.00 | 0.00 |
| EBITDA | -12.11M | -14.50M | -17.82M | -13.90M | -23.93M | -26.62M | -17.67M | -8.60M | -6.83M | -1.07M | -8.52M |
| EBITDA Ratio | -1,879.97% | -2,044.73% | -3,439.08% | -2,132.68% | -2,535.09% | -5,147.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.43M | -14.76M | -18.14M | -14.39M | -24.00M | -26.68M | -22.85M | -10.37M | -8.86M | -1.07M | -8.52M |
| Operating Income Ratio | -1,929.81% | -1,875.35% | -3,475.48% | -2,176.40% | -1,604.01% | -5,580.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.58M | 687.00K | 10.00K | 72.00K | 14.22M | -1.95M | -5.17M | -1.67M | 1.98M | 0.00 | 0.00 |
| Income Before Tax | -8.85M | -14.07M | -18.13M | -14.13M | -9.78M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | -8.52M |
| Income Before Tax Ratio | -1,374.22% | -1,788.06% | -3,473.56% | -2,137.67% | -653.81% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.51M | -10.00K | -193.00K | -14.12M | 3.96M | 10.34M | 1.67M | -146.62K | 0.00 | -8.52M |
| Net Income | -8.85M | -12.56M | -18.12M | -13.94M | 4.34M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | 0.00 |
| Net Income Ratio | -1,374.22% | -1,595.68% | -3,471.65% | -2,108.47% | 290.04% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| EPS Diluted | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and...
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors -- -- Results will support...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and...
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances through the Company's At-The-Market (“ATM”) program extends cash runway...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical program feasibility streamlines cost and timeline and leverages trials with the Medical University of South...
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in...
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
The mean of analysts' price targets for Helius Medical Technologies, Inc. (HSDT) points to a 1249.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate...
Source: https://incomestatements.info
Category: Stock Reports